|
AU2008203540A1
|
|
Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
|
|
HU0700252D0
|
|
Dioxo-thiazolidinedione derivative and it's use as antidiabetic
|
|
AU2005248930A1
|
|
Pharmaceutical formulation
|
|
AU2005229688A1
|
|
Tartrate salts of thiazolidinedione derivative
|
|
AU2005229694A1
|
|
Tartrate salt of thiazolidinedione derivative
|
|
AU2005229687A1
|
|
Tartrate salts of thiazolidinedione derivative
|
|
AU2005227371A1
|
|
Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide
|
|
US2005260714A1
|
|
Novel compounds
|
|
AU2005200704A1
|
|
Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
|
|
HK1068616A1
|
|
Rosiglitazone edisylates and their use as antidiabetics
|
|
US2005214905A1
|
|
Novel compounds
|
|
TW200526274A
|
|
Pharmaceutical formulations
|
|
US2004248945A1
|
|
Thiazolidinedione derivative and its use as antidiabetic
|
|
HK1061392A1
|
|
5-'4-'2-(N-methyl-n-(2-pyridyl)amino)ethoxyÜbenzylÜthiazolidine-2,4-dione mesylate salt
|
|
US2004176370A1
|
|
3,4-Dihdro-N-[[1-(3-hydroxybutyl)-4-piperidinyl]methyl]-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide as 5-HT(4) receptor antagonist
|
|
US2004082041A1
|
|
Process for the preparation of pharmaceutically active thiazolidine or oxazolidine compounds by a yeast reductase
|
|
US2004081697A1
|
|
Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
|
|
US2006205641A1
|
|
VANILREP4 polypeptides and VANILREP4 polynucleotides
|
|
US2004038315A1
|
|
Novel method
|
|
GB0318236D0
|
|
Process
|
